Virbac Group (Virbac) focuses on development and manufacturing of vaccines for domestic animals and livestock. The company’s drugs help prevent and cure certain animal diseases. The company has presence in over 100 countries across the world. It operates through three reportable segments, namely, Companion Animals, Food Producing Animals and Other businesses. As of December, 31, 2022, the company operated over 33 countries.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D focuses on the development of vaccines for companion animals; and innovative and original formulations for companion animals, ruminants, pigs, and aquaculture channels. It is focused on advancing its technologies to provide products based on the unmet needs of the market. Virbac operates R&D centers in nine countries; France, the US, Australia, Mexico, Vietnam, Taiwan, Chile, China and Uruguay. In FY2022, the company adopted a Corporate Biological R&D organization and a Pharmaceutical R&D organization.